Our Neuromuscular Program doctors are recognized experts in caring for all types of spinal muscular atrophy.
As a designated Muscular Dystrophy Association Care Center, we provide a team-based approach to care that brings together many specialists, including neurologists, geneticists, pulmonologists, and physical, occupational, speech and language pathologists, as well as respiratory, and other therapists.
We work together in real-time to create a comprehensive care plan. We work closely with our colleagues in Pediatric and Adult Neurology to bring you the care you need. This allows for a seamless transition, and continuity of care, when children become adults and transfer from the children’s hospital to Stanford. In fact, many of our team members work at both the children’s clinic and the adult clinic.
Features of our clinic include:
SMA Drug Therapy
Our doctors helped develop a disease-modifying drug, Spinraza, and treated the first adult ever, after FDA approval. The drug helps the surviving motor neuron (SMN2) gene make the SMN protein work more efficiently and improve the health of the nerves that control muscles.
Determining Eligibility for Spinraza Treatment
Our team determines if you will be eligible for the drug after baseline tests, including a genetic test, imaging, labs, and physical therapy assessment, and we work with your insurance company to obtain approval. Once your insurance authorization is complete, you will receive four injections in the first two months and injections every four months after.